Elevidys access in the UAE: the EDE named-patient pathway
How UAE families with a child diagnosed with Duchenne muscular dystrophy access Elevidys (delandistrogene moxeparvovec), the AAV-based DMD gene therapy, when local registration, certified-center capability, or payer reality does not match the prescribed plan.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
Quick orientation
Elevidys (delandistrogene moxeparvovec-rokl) is an AAVrh74-based one-time gene therapy delivering a transgene encoding micro-dystrophin, approved by the US FDA on 22 June 2023 for ambulatory pediatric patients aged 4 through 5 with Duchenne muscular dystrophy and a confirmed mutation in the DMD gene, and expanded on 20 June 2024 to ambulatory patients 4 years and older and non-ambulatory patients 4 years and older with a confirmed DMD mutation. It is the first and only gene therapy approved for DMD. The drug is not currently registered with the UAE's regulatory authorities for commercial sale, so UAE families reach it through the federal named-patient import pathway administered, from 29 December 2025 under Federal Decree-Law No. 38 of 2024, through the Emirates Drug Establishment (EDE). Reserve Meds coordinates the US-side sourcing, frozen cold-chain logistics, and the documentation kit the treating pediatric neurology team needs to file with the EDE.
Reserved for you.
Why UAE families need Elevidys through the named-patient pathway
Duchenne muscular dystrophy is an X-linked recessive disease driven by mutations in the DMD gene that disrupt dystrophin production. Approximately 1 in 3,500 to 1 in 5,000 male births is affected worldwide; the UAE-specific prevalence is consistent with this global range, and the consanguinity-driven inheritance pattern in the Gulf Cooperation Council region surfaces a small but visible cohort of confirmed DMD cases at the tertiary pediatric neurology programs of Sheikh Khalifa Medical City, Cleveland Clinic Abu Dhabi, and SEHA's pediatric specialty footprint. UAE newborn screening is expanding and the genetic confirmation pathway through MOHAP's medical genetics service and private genomics labs (Genomics Center, Mubadala-affiliated programs) is increasingly accessible.
The access gap for Elevidys in the UAE sits in four layers. First, regulatory: Sarepta has not filed Elevidys for UAE commercial registration as of this page date. Second, certified-center capability: AAV gene therapy infusion requires a pediatric institution with infusion suite, post-infusion ICU backup, and the immunomonitoring infrastructure for the post-infusion period; the count of qualified UAE sites is narrow. Third, eligibility gating: anti-AAVrh74 antibody titer must be below the FDA-labeled threshold, the patient must have a confirmed DMD mutation (typically by next-generation sequencing or multiplex ligation-dependent probe amplification), and the family must accept the boxed-warning context for serious immune-mediated myositis. Fourth, payer reality at USD 3.2 million list price: Daman, GIG Gulf, Sukoon, ADNIC, and Orient assess multi-million-dollar one-time gene therapies case by case, and most commercial plans fall short of full coverage. Cash-pay funded through family resources is the most common operating posture.
The clinical case for Elevidys is time-sensitive in a different way than Zolgensma. Disease-modifying benefit in DMD is greatest when delivered before substantial muscle loss has occurred; while the FDA label opened administration to non-ambulatory patients in June 2024, the treating pediatric neurology team typically wants to act inside a window that preserves remaining ambulatory function or, for non-ambulatory candidates, before respiratory and cardiac involvement becomes the dominant clinical problem. Families who reach us are typically working against an active disease trajectory, not a stable one.
The EDE named-patient pathway for Elevidys
The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered or not stocked locally is the unregistered-medicine import permit, historically administered by MOHAP and, from 29 December 2025, administered through the EDE portal at ede.gov.ae. The framework allows hospitals and licensed pharmaceutical establishments to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA for Elevidys, given no EMA or MHRA approval at this page date) and a clinically equivalent locally registered alternative is not suitable.
For Elevidys specifically, the clinical-justification angle that anchors the application is genetic confirmation plus institutional gene-therapy readiness. The strongest applications consistently document: a confirmed DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory (NGS report with the deletion, duplication, or point mutation specified); the patient's age (4 years or older) and ambulatory or non-ambulatory status; the baseline North Star Ambulatory Assessment (NSAA) score or equivalent functional measure for ambulatory cases, or baseline upper-limb function and respiratory measures for non-ambulatory cases; the anti-AAVrh74 binding antibody titer (must be below the FDA-labeled threshold per the validated assay); the immunosuppression plan for the peri-infusion period (typically oral prednisone or equivalent starting one day before infusion and continuing for at least 60 days, with taper guided by clinical and laboratory parameters); the receiving institution's gene therapy infusion capability, pediatric critical care backup, and laboratory infrastructure for the post-infusion creatine kinase, troponin, liver function, and platelet monitoring window; and the case for why the FDA-approved indication is appropriate for this specific patient given the locally available alternatives (in the UAE: corticosteroids including deflazacort and prednisone, exon-skipping therapies including eteplirsen for exon 51 amenable patients, viltolarsen and golodirsen for exon 53, casimersen for exon 45, and supportive care).
A complete EDE application includes the clinical justification letter from the treating pediatric neurologist with active MOHAP, DHA, DOH, or Sharjah Health Authority licensing (depending on practice emirate), the genetic test report attached as a supporting document, the anti-AAVrh74 titer result, the proposed dosing plan at the FDA-labeled 1.33 x 10^14 vg/kg delivered as a single intravenous infusion, the destination dispensing facility license and pharmacy in charge, and the chain-of-custody plan describing how the medicine will move from the Sarepta manufacturing facility through the importer to the dispensing pharmacy, including the frozen cold-chain handling at minus 60 degrees Celsius or colder. Approval timelines for routine cases run 10 to 21 business days; complex first-time gene-therapy imports can extend to 4 to 8 weeks.
Where Elevidys gets dispensed in the UAE
The treating-center map for Elevidys in the UAE is narrow because of the AAV gene therapy infusion capability requirement. The institutions most likely to handle a UAE Elevidys case are Cleveland Clinic Abu Dhabi on Al Maryah Island (M42 group, ASHP-accredited pharmacy, pediatric neurology and critical care capability), Sheikh Khalifa Medical City in Abu Dhabi (SEHA-network 586-bed JCI-accredited tertiary hospital with pediatric specialty footprint), Tawam Hospital in Al Ain (SEHA-network referral center with pediatric services), American Hospital Dubai (Mayo Clinic Care Network member, multi-specialty pediatric services), and King's College Hospital London Dubai. Mediclinic City Hospital in Dubai Healthcare City and the larger NMC Healthcare sites participate in named-patient workflow but the gene-therapy administration itself depends on the institution's pediatric gene therapy and critical care readiness on the relevant date.
The dispensing facility must hold validated frozen storage at minus 60 degrees Celsius or colder, gene therapy infusion suite capability, pediatric critical care backup, and laboratory turnaround for the post-infusion monitoring schedule including weekly creatine kinase, troponin, AST, ALT, total bilirubin, and platelet count for the first 90 days. The receiving institution also carries the peri-infusion corticosteroid course (oral prednisone 1 mg/kg/day or equivalent starting one day before infusion, continuing for at least 60 days, with taper based on clinical and laboratory parameters).
Real cost picture for Elevidys in the UAE
US wholesale acquisition cost for Elevidys is approximately USD 3.2 million per single-dose treatment course, the highest list price for any FDA-approved gene therapy as of this page date. At the AED 3.67 peg, the cell-product price converts to approximately AED 11.75 million. This is a one-time price and reflects the entire therapy.
International logistics for the frozen shipper from the Sarepta manufacturing facility to the receiving UAE pediatric center add a defined surcharge in the AED 18,000 to AED 55,000 range (USD 5,000 to USD 15,000), with customs pre-clearance handled in parallel to preserve the validated shipping window. The receiving institution's procedural and inpatient costs (gene therapy infusion suite, peri-infusion corticosteroid course, post-infusion monitoring labs across the first three months, pediatric critical care standby) are the institution's line items, not Reserve Meds'. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the payer side, UAE insurer behavior at the USD 3.2 million price point is restrictive. Daman, Thiqa (the government-funded program for UAE nationals administered by Daman), GIG Gulf, Sukoon, ADNIC, and Orient each assess pediatric gene therapy case by case, with most commercial plans falling short of full coverage. Thiqa has the broadest specialty coverage in Abu Dhabi for UAE nationals and is the most likely source of meaningful institutional support for an Emirati family with a confirmed DMD diagnosis. Sovereign-tied pathways through Department of Health Abu Dhabi or Dubai Health Authority for UAE nationals are case-by-case. We do not promise coverage from any insurer or scheme.
Typical timeline for Elevidys in the UAE
EDE routine processing is typically 10 to 21 business days from a complete filing. For Elevidys specifically, the frozen shipper logistics and customs pre-clearance run in parallel with the regulatory filing rather than in sequence. End-to-end from family decision to infusion day, the typical achievable window is six to ten weeks. The anti-AAVrh74 antibody titer test result is the earliest gating event; if the titer is above the FDA-labeled threshold, the case pauses for retest consideration before the frozen shipper is staged. The peri-infusion corticosteroid course starts one day before infusion; the post-infusion monitoring window extends three months actively and longer for the structured pharmacovigilance follow-up.
What your physician needs to provide
For a UAE-licensed pediatric neurologist prescribing Elevidys through the EDE pathway, the clinical justification letter is the cornerstone of the application. The letter, signed with active MOHAP, DHA, DOH, or Sharjah Health Authority registration, documents the DMD diagnosis with the specific dystrophin gene mutation reported by a named genetics laboratory, the patient's age (4 years or older), ambulatory or non-ambulatory status, baseline functional assessment (NSAA for ambulatory; Performance of the Upper Limb scale and respiratory measures for non-ambulatory), the anti-AAVrh74 binding antibody titer result with the validated assay named, the immunosuppression plan, and the dosing at 1.33 x 10^14 vg/kg delivered as a single intravenous infusion.
The monitoring plan covers weekly creatine kinase, troponin-I, AST, ALT, total bilirubin, and platelet count for the first 90 days, with the boxed-warning vigilance for serious immune-mediated myositis (presenting with severe muscle weakness, severe creatine kinase elevation, troponin elevation, or both, typically within the first three months after infusion). The treating physician's UAE license number, the dispensing facility's license, and the pharmacy in charge of dispensing complete the package. Adverse event reporting to the UAE Pharmacovigilance Center is referenced in the documentation kit; reporting obligations remain with the prescribing physician and the institution.
Common questions about Elevidys in the UAE
Is Elevidys registered in the UAE? Not at this page date. Sarepta has not filed Elevidys for UAE commercial registration. Access for UAE families runs through the EDE named-patient pathway with US-source supply under DSCSA chain-of-custody documentation.
My son is 3 years old. Can he still receive Elevidys? The FDA label is patients 4 years and older. Under-4 cases are off-label and require a separate clinical justification not part of the standard EDE named-patient pathway. The treating pediatric neurology team makes the final eligibility call.
What if the anti-AAVrh74 antibody titer is too high? A titer above the FDA-labeled threshold by the validated assay is an eligibility exclusion at the time of testing. The treating pediatric neurology team determines retest cadence; in some cases titers can fall over time. If the titer remains elevated, the case typically pivots to ongoing exon-skipping therapy or other supportive interventions.
Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover the USD 3.2 million list price? UAE insurers assess multi-million-dollar one-time gene therapies case by case. Most commercial plans fall short of full coverage. Thiqa has the broadest specialty coverage in Abu Dhabi for UAE nationals and is the most likely source of meaningful institutional support. Sovereign-tied pathways may apply for select cases. We do not promise coverage from any source. Cash-pay funded through family resources is the default operating posture for Reserve Meds-coordinated cases.
How does Elevidys interact with exon-skipping therapies my son is already on? Patients on eteplirsen, viltolarsen, golodirsen, or casimersen may discontinue exon-skipping therapy at or around the time of Elevidys infusion based on the treating neurologist's clinical judgment, since the gene therapy is intended to provide ongoing micro-dystrophin expression. The decision sequence rests with the treating team and is not a question Reserve Meds answers.
What is the boxed-warning serious immune-mediated myositis I keep reading about? Severe muscle weakness, severe creatine kinase elevation, and troponin elevation in the first three months after infusion are the labeled risk for serious immune-mediated myositis. The receiving institution carries the weekly laboratory monitoring through the structured window, with corticosteroid escalation, IVIG, and other immunomodulation as the clinical response pathway. The family receives clear instructions on warning signs and a direct phone line to the institution between visits.
Can the medicine be administered in Sharjah, Ajman, or the Northern Emirates? The dispensing facility must hold gene therapy infusion capability, pediatric critical care backup, and validated minus 60 degrees Celsius storage. In practice this concentrates the administration at the tertiary pediatric centers in Abu Dhabi and Dubai. Pre- and post-infusion follow-up can be coordinated with the family's home-emirate neurologist in coordination with the originating institution.
Where Reserve Meds fits in Elevidys cases
Reserve Meds is a US-based concierge coordinator. We do not replace your pediatric neurologist, we do not replace the EDE, and we do not replace the receiving institution's gene therapy and critical care infrastructure. For Elevidys specifically, we orchestrate the US-side sourcing through Sarepta's qualified channel under DSCSA chain-of-custody, build the documentation kit your physician submits to the EDE, coordinate frozen cold-chain logistics with continuous temperature logging into the UAE, pre-stage customs clearance in parallel with regulatory filing, and assign a single named coordinator through the case. The clinical decisions remain with the treating pediatric neurology and gene therapy team; the regulatory authority remains the EDE; the gene therapy delivery remains with the qualified UAE institution.
Next step
If your pediatric neurologist has diagnosed DMD in your son and you are weighing the Elevidys cross-border route, the next step is a short waitlist request. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.